(888) 552-6760 SCHEDULE A CONSULTATION
Clinical-Trials

Clinical trials

Search our clinical trials

Cancer Treatment Centers of America® (CTCA) is committed to providing new and innovative treatments for our cancer patients whenever possible. This includes enrolling qualified patients in carefully selected clinical trials for cancer. Clinical trials are a key testing ground for determining the effectiveness and safety of new treatments and drugs for cancer and other diseases. Our doctors may recommend that cancer patients enroll in cancer clinical trials if they meet specific criteria. Cancer trials may offer patients access to treatment options that would otherwise be unavailable to them. Talk to your doctor about whether a cancer trial is a good option for you and ask about the risks and various requirements involved. Use the tool below to find a CTCA® clinical trial for your cancer type.

Filters

10 Clinical Trials

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a trial of SAR408701 versus docetaxel in previously treated, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) positive metastatic non-squamous non-small cell lung cancer patients.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov
     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The main purpose of this study is to assess efficacy, safety, tolerability and pharmacokinetics (PK) of Berzosertib in combination with Topotecan in participants with relapsed, platinum-resistant small-cell lung cancer (SCLC). This study will be conducted in two parts: safety run-in part and main part. The safety run-in part will be conducted in Japan.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the MET inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in participants with advanced or metastatic NSCLC.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

The expected duration of study intervention for participants who benefit from study intervention may vary, based on progression date; but median expected duration of study per participant is estimated as median nine months in docetaxel arm (one month for screening, four months for treatment, and four months for the end of treatment and follow-up visits) and 12.5 months in SAR408701 arm (one month for screening, 6.5 months for treatment, and five months for end of treatment follow-up).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This trial will evaluate the safety and efficacy of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy before surgery (neoadjuvant phase), followed by pembrolizumab alone after surgery (adjuvant phase) in participants with resectable stage IIB or IIIA non-small cell lung cancer (NSCLC).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This phase II/III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer.

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is a phase II, open-label, multicenter study to evaluate the efficacy and the safety/tolerability of poziotinib in up to 174 patients with NSCLC exon 20 insertion mutations (87 patients with EGFR exon 20 insertion mutations and 87 patients with HER2 exon 20 insertion mutations).

     

Accepting new patients

 

Learn more at

clinicaltrials.gov

This is an open-label, multicenter, global phase II basket study of entrectinib (RXDX-101) for the treatment of participants with solid tumors that harbor an NTRK1/2/3, ROS1 or ALK gene fusion. Participants will be assigned to different baskets according to tumor type and gene fusion.

This study will evaluate the safety (side effects) and antitumor activity of study drug in men and women with advanced cancer, based on certain types of DNA defect or damage.